Peptides

Matches 251 - 300 out of 23,148	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/236913A1	IMMUNE CELLS TARGETING EPCAM AND MEDICAL USE THEREOF The present invention relates to the technical field of biomedicine, and specifically relates to immune cells targeting EpCAM and a medical use thereof. Provided is a use of immune cells in the preparation of a drug for preventing or tre...
WO/2023/236980A1	PHARMACEUTICAL COMPOSITION OF PVRIG/TIGIT BISPECIFIC ANTIBODY AND USE THEREOF Provided are a pharmaceutical composition of a PVRIG/TIGIT bispecific antibody and use thereof. Specifically, provided is a pharmaceutical composition, comprising a PVRIG/TIGIT bispecific antibody and a buffer solution. The pharmaceutica...
WO/2023/173084A9	CYCLOPEPTIBODIES AND USES THEREOF Methods and compositions for generating novel proteins comprise a genetically encoded macrocyclic peptide fused to an immunoglobulin Fc region, referred to as "cyclopeptibodies." Methods and compositions are provided for making cyclopept...
WO/2023/239265A1	HYBRID GENE FOR PRODUCING RECOMBINANT RBD ANTIGEN The invention relates to biotechnology, immunology and virology, and more particularly to the creation of a vaccine against coronavirus infection and to a method for producing same, for producing a hybrid gene that codes for the recombin...
WO/2023/236468A1	CORONAVIRUS S PROTEIN VARIANT AND USE THEREOF Provided is an S protein variant, which does not contain a complete cytoplasmic tail domain compared to the S protein of a wild-type coronavirus. Further provided are a nucleic acid molecule encoding the S protein variant, and the use of...
WO/2023/237774A1	FUSION PROTEIN FOR MAINTENANCE OF REGULATORY T-CELLS The present invention relates to a fusion protein that provides for maintenance of regulatory T-cells that are polyclonal, e.g. natural isolated antigen-specific Treg cells, and/or Treg cells generated by introduction of a nucleic acid c...
WO/2023/235971A1	ANTIBODIES AND IMMUNOTHERAPIES THAT TARGET THE ACTIVE CONFORMATION OF INTEGRIN BETA 2 Provided herein are antibodies to active integrin beta-2 and compositions comprising such antibodies for the treatment of a cancer, e.g., acute myeloid leukemia.
WO/2023/236954A1	PD-1 VARIANT AND USE THEREOF The present invention relates to a PD-1 variant and the use thereof. Specifically, the PD-1 variant of the present invention can bind to PD-L1 with high affinity, but does not bind to one or more anti-PD-1 monoclonal antibodies, and pref...
WO/2023/238127A1	UBIQUITIN HIGH AFFINITY CYCLIC PEPTIDES AND METHODS OF USE THEREOF The present invention provides cyclic peptides, as well as methods of using the same, such as for ameliorating or treating a K63Ub-related disease in a subject in need thereof.
WO/2023/236726A1	IMMUNE ADJUVANT BASED ON METALLOTHIONEIN FAMILY AND USE THEREOF Disclosed is use of a metallothionein as an immune adjuvant. The use of the metallothionein with an immunogenic antigen in the form of a fusion protein or a composition can quickly, efficiently, and permanently excite an antigen-specific...
WO/2023/230729A1	SYNTHETIC ANTIGEN RECEPTORS FOR COVALENT IMMUNE RECRUITERS AND METHODS AND USES THEREOF The present description relates to synthetic antigen receptors for use with covalent immune recruiters (CIRs) comprising an donor moiety, a covalent binding group, and a target binding domain (TBD), the synthetic antigen receptor compris...
WO/2023/232022A1	RECOMBINANT FUSION PROTEIN TARGETING PD-L1 AND VEGF, AND PREPARATION AND USE THEREOF The present application provides a recombinant fusion protein, comprising 1) a PD-L1 antibody or an antigen-binding fragment thereof, and 2) a VEGF-binding peptide, the N-terminus of a heavy chain or a light chain of the PD-L1 antibody o...
WO/2023/231969A1	INSULIN HYBRID PEPTIDE COMPRISING CHYMOTRYPSIN INHIBITORY PEPTIDE, AND USE THEREOF The present invention belongs to the field of protein engineering, and relates to a hybrid peptide formed by a chymotrypsin inhibitory peptide and insulin or an analogue thereof. The heterozygous insulin analogue can resist the degradati...
WO/2023/235648A1	Nuclear Delivery and Transcriptional Repression with a Cell-penetrant MeCP2 Methods and compositions for nuclear delivery and transcriptional repression employ a cell-penetrant MeCP2 fusion protein.
WO/2023/234416A1	AFFINITY SUBSTANCE, COMPOUND, AND ANTIBODY AND THEIR SALTS The present invention relates to a technology for facile chemical modification of only one heavy chain in an antibody structural unit (immunoglobulin unit comprising two heavy chains and optionally two light chains). More specifically, t...
WO/2023/231705A1	BISPECIFIC ANTIBODY TARGETING SIRPα AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE A bispecific antibody targeting SIRPα and PD-L1 or an antigen-binding fragment thereof and a use. The bispecific antibody comprises an SIRPα binding domain and a PD-L1 binding domain; the SIRPα binding domain comprises a heavy chain v...
WO/2023/231888A1	ANTI-HUMAN GROWTH HORMONE SINGLE-DOMAIN ANTIBODY AND USE THEREOF The present invention relates to a single-domain antibody or an antigen-binding fragment thereof specifically binding to human growth hormone, a conjugate containing the single-domain antibody or the antigen-binding fragment thereof, a n...
WO/2023/234300A1	MODIFIED VACCINE DESIGN DEVELOPMENTS Provided herein is an isolated polynucleotide, which encodes a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. Also provided herein is an isolated polynucleotid...
WO/2023/207574A9	RECOMBINANT HARSA FOR CROSSING BLOOD-BRAIN BARRIER Provided is a fusion protein, comprising: a transferrin-binding protein, and arylsulfatase A (ARSA) or a functional active fragment thereof. The transferrin-binding protein comprises a polypeptide, an antibody or an antigen-binding fragm...
WO/2023/225802A1	TREFOIL FACTOR 2/INTERFERON α2 FUSION PROTEIN AND APPLICATION THEREOF IN PREVENTION AND TREATMENT OF VIRAL INFECTIOUS DISEASES The present disclosure provides a trefoil factor 2 (TFF2)/interferon α2 (IFNα2) fusion protein and an application thereof in prevention and treatment of viral infectious diseases. Specifically, the present disclosure provides a fusion ...
WO/2023/229029A1	HETERODIMERIC PROTEIN PRODUCTION METHOD, DIMERIC PROTEIN, MONOMERIC PROTEIN, AND TARGET RESPONSIVE HETERODIMERIC PROTEIN SCREENING METHOD Provided is a heterodimeric protein production method for heterodimeric proteins such as bispecific antibodies, by which it is possible to produce a heterodimeric protein composed solely of domains comprising natural amino acid sequences...
WO/2023/226836A1	CHIMERIC ANTIGEN RECEPTOR CONTAINING CLDN18.2 SINGLE DOMAIN ANTIBODY AND APPLICATION THEREOF A chimeric antigen receptor containing a CLDN18.2 single domain antibody and an application thereof. The constructed chimeric antigen receptor is good in specificity, higher in safety in vivo use, and smaller in toxicity, and can provide...
WO/2023/226988A1	METHOD FOR ENHANCING IMMUNOGENICITY OF SARS-COV-2 VARIANT AND USE THEREOF Disclosed herein are a method for enhancing the immunogenicity of an SARS-CoV-2 variant and use thereof. By means of point mutation on certain amino acid positions of the spike protein of the SARS-CoV-2 variant, the present invention enh...
WO/2023/227018A1	FUSION PROTEIN TARGETING CELL MEMBRANE RECEPTOR PROTEINS AND USE THEREOF Provided in the present disclosure are fusion protein targeting cell membrane receptor proteins and the use thereof. The fusion protein targeting the cell membrane receptor proteins can promote the endocytosis of membrane receptor protei...
WO/2023/227015A1	FVIII FUSION PROTEIN CONJUGATE HAVING EXTENDED HALF-LIFE AND USE THEREOF Provided in the present disclosure are a blood coagulation factor VIII-Fc fusion protein conjugated to polyethylene glycol and having an extended cyclic half-life, a preparation method therefor, and the use thereof.
WO/2023/227134A1	LONG-ACTING IL5 NANOBODY AND USE A long-acting IL5 nanobody and use. The long-acting IL5 nanobody comprises a bivalent nanobody targeting IL5 and a nanobody targeting HSA, wherein the bivalent nanobody targeting IL5 comprises an IL5 VHH1 and an IL5 VHH2, and the amino a...
WO/2023/227028A1	NOVEL CAS EFFECTOR PROTEIN, GENE EDITING SYSTEM, AND USE The present invention provides a novel Cas effector protein, a gene editing system, and a use. The Cas effector protein is CasRfg.3 and a similar protein thereof. The CasRfg.3 protein (also known as Ca2) of the present invention has a re...
WO/2023/230316A1	RIBOZYME-ASSISTED CIRCULAR RNAS AND COMPOSITIONS AND METHODS OF USE THERE OF The disclosure features compositions, systems, and methods for preparation and use of efficient RNA nuclear export of ribozyme-assisted circular RNA molecules (racRNAs). In embodiments, the methods involve characterizing a cell or tissue...
WO/2023/222040A1	RECOMBINANT ERYTHROPOIETIN AND APPLICATION THEREOF The present invention relates to a recombinant erythropoietin, a nucleic acid molecule encoding same, a fusion protein comprising same, an expression vector, host cell and composition thereof, and an application thereof. The recombinant ...
WO/2023/220781A1	BETA-PEPTIDES AND BETA-PEPTIDE HYDROGELS The present invention relates to β-peptides and hydrogels comprising the β-peptides. The hydrogels may further comprise a therapeutic cargo encapsulated within the hydrogel. Methods of preparing the hydrogels, and methods for the use o...
WO/2023/222035A1	FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF, AND APPLICATION THEREOF The present disclosure provides a fusion protein of an anti-TIGIT antibody and IL2, a variant thereof, and an application thereof. Specifically, the present disclosure provides a fusion protein, comprising: (a) a first polypeptide, which...
WO/2023/221935A1	ANTIBODY BINDING TO PD-L1 AND CLDN18.2 AND USE THEREOF The present invention provides an antibody. The antibody can specifically bind to human CLDN18.2 and human PD-L1. The present invention further provides a nucleic acid molecule encoding the antibody, an expression vector for expressing t...
WO/2023/220842A1	A FUSION PROTEIN AS A SUBUNIT VACCINE IMMUNOGEN AGAINST SARS-COV-2 AND THE PREPARATION THEREOF Provided is a fusion protein as a subunit vaccine immunogen against SARS-CoV-2 comprising of receptor binding domain (RBD) fragment of SARS-CoV-2 spike protein and Tetanus toxoid fragment P2, they are fused by a linker sequence. Also pro...
WO/2023/217216A1	DESIGN, PREPRATION, AND USE OF TRI-SPECIFIC ANTIBODY The present invention provides design of a tri-specific antibody, a preparation method for the trispecific antibody, and use of the tri-specific antibody. The tri-specific antibody of the present invention comprises (a) an anti-Her2 mono...
WO/2023/217206A1	NOVEL CORONAVIRUS CHIMERIC NUCLEIC ACID VACCINE AND USE THEREOF A polynucleotide, a related product thereof, a use thereof in the preparation of a novel coronavirus vaccine, and a chimeric nucleic acid vaccine or immunogenic composition based on the polynucleotide; the polynucleotide encodes a recomb...
WO/2023/217062A1	CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF The present application relates to a chimeric antigen receptor, which comprises an extracellular antigen binding domain, wherein the extracellular antigen binding domain comprises a first antigen binding domain and a second antigen bindi...
WO/2023/216897A1	MUTANT HPPD POLYPEPTIDE AND USE THEREOF The present invention provides a herbicide resistance gene, a polypeptide, and use thereof in plant breeding. Specifically, the present invention provides a mutant HPPD polypeptide and use thereof. Compared with a parent HPPD polypeptide...
WO/2023/217005A1	TANDEM-TYPE HYBRID TRIMERIC SARS-COV-2 VACCINE Disclosed in the present invention are a recombinant chimeric antigen of the prototype strain and Delta and Omicron variant strains of SARS-CoV-2, a preparation method therefor, and the use thereof. The recombinant chimeric antigen is fo...
WO/2023/216623A1	CAMEL-DERIVED HIGH-AFFINITY NANOANTIBODY AGAINST SARS-COV-2 α, γ, δ AND ο MUTANTS The present invention relates to a camel-derived high-affinity nanoantibody against SARS-CoV-2 α, γ, δ and ο mutants, specifically relates to an antibody specifically binding to an S protein of a novel coronavirus (SARS-CoV-2) and an...
WO/2023/216415A1	BASE EDITING SYSTEM BASED ON BIMOLECULAR DEAMINASE COMPLEMENTATION, AND USE THEREOF A base editing system based on bimolecular deaminase complementation, and use thereof. The base editing system is mainly composed of nCas9 and nucleobase deaminase double complementary base editing fusion proteins A and B, as well as a g...
WO/2023/217288A1	NOVEL FUSION PROTEIN AND USE THEREOF Provided are modifications of human interleukin-2 (IL-2) and interferon α (IFNα), a fusion protein formed by modified IL-2, IFNα, or both of IL-2/IFNα and an Fc, and design, preparation and use of the fusion protein. By changing the ...
WO/2023/217192A1	PREPARATION OF CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL CONSTRUCTED BASED ON MSLN PRECURSOR PROTEIN AND USE THEREOF The present invention provides preparation of a chimeric antigen receptor immune cell constructed based on an MSLN precursor protein and use thereof. Specifically, the present invention provides a chimeric antigen receptor (CAR) modified...
WO/2023/216218A1	ANTIBODY SPECIFICALLY BINDING TO CD22, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present application belongs to the technical field of biological immunity, and specifically relates to a monoclonal antibody capable of specifically binding to CD22 and an antigen-binding fragment thereof. The present application fur...
WO/2023/216981A1	FUSION PROTEIN OF RELAXIN OR ANALOGUE AND MEDICAL USE THEREOF The present disclosure relates to a fusion protein of relaxin or an analogue and the medical use thereof. Specifically, the present disclosure relates to a fusion protein comprising relaxin or an analogue thereof and a serum albumin bind...
WO/2023/217904A1	SYNCITIN-1 FUSION PROTEINS AND USES THEREOF FOR CARGO DELIVERY INTO TARGET CELLS The inventors developed a new system to modify tropism of syncytins, envelope proteins, which can be used to functionalize particles such as virus particle or more particularly viral- like particles (VLPs), and used for gene transfer or ...
WO/2023/213290A1	RECOMBINANT FUSION PROTEIN TARGETING CD40 AND CD47 Provided is a recombinant fusion protein comprising (a) an anti-CD40 antibody or an antigen binding portion thereof comprising a heavy chain variable region and a light chain variable region, and (b) a CD47 binding domain. Provided is a ...
WO/2023/215259A1	TRANSCRIPTION ACTIVATORS AND PROGRAMMABLE TRANSCRIPTION ENGINEERING Methods and materials for stimulating expression of target genes in plants are provided herein.
WO/2023/213010A1	METHOD FOR PRODUCING CHIMERIC SILK USING BOMBYX MORI BY MEANS OF AUTOGRAPHA CALIFORNICA NUCLEAR POLYHEDROSIS VIRUS Disclosed is a method for producing chimeric silk using bombyx mori by means of autographa californica nuclear polyhedrosis virus, comprising: constructing a plasmid pFAST-FibL-MaSp-c containing an FibL-MaSp-c-polyA FibL fragment, transf...
WO/2023/213280A1	CHIMERIC ANTIGEN T CELL RECEPTOR TARGETING CLDN18.2 AND USE THEREOF The present application relates to a chimeric antigen receptor targeting CLDN18.2 and use thereof, and provides a chimeric antigen receptor targeting CLDN18.2, a nucleic acid molecule, a vector, an immune cell, a method for preparing sam...
WO/2023/213969A1	VIRAL-BINDING PROTEIN AND RELATED REAGENTS, ARTICLES, AND METHODS OF USE Provided herein are proteins comprising a viral-binding domain and reagents comprising same. In some aspects, the provided proteins and reagents can be used for the purification of viral particles. In some aspects, the provided proteins ...

Matches 251 - 300 out of 23,148	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >